Financial writer recommends buying Rubrik stock with a $48 target, citing strong growth and high customer expansion rates.

Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...

Discover more on Sitio Royalties' production growth and guidance, emphasizing share repurchases over dividends and potential ...

Crude oil futures fell slightly on Friday but posted their second straight weekly gain in volatile trading marked by ...

Talen Energy stock fell after PJM Interconnection delays capacity auction by around six months to give it time to address a ...

The PGIM Global High Yield Fund offers a 9.86% yield but faces potential downside risks. Learn more about PGIM CEF and its ...

Boeing (BA) announcing workforce cuts, delayed jet delivery, and $5B in earnings charges, while Q3 preliminary revenues miss ...

Wells Fargo's Q3 earnings exceeded expectations, and management is doing a great job despite regulatory constraints. Learn ...

Chinese equities soared on the back of the recent monetary stimulus moves that included rate cuts and loosening purchase ...

The iShares 20+ Year Treasury Bond is a long-term buy in the $89-$94 region as it has a decent yield and is positioned to ...

Amazon's ability to recalibrate its operating margins and drive operating leverage growth further demonstrates its incredible ...

Following a Q1 earnings miss, Neogen's outlook appears uncertain. Explore insights on NEOG stock and when a growth rebound ...